Last viewed:
AMRX
Prices are updated after-hours
AMRX
|
$6.05
12.04%
11.04%
2.7M
|
Health Technology
(0.0% 1d)
(3.4% 1m)
(234.3% 1y)
(0.0% 2d)
(12.0% 3d)
(11.6% 7d)
(121.87%
volume)
Earnings Calendar:
Market Cap: $ 1,866,753,079
http://www.amneal.com
Sec
Filling
|
Patents
| 5500 employees
Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.
injection
dividends
Drugs
Zolmitriptan
(Zolmitriptan )
ZOMIG
(Zolmitriptan )
ZOMIG ZMT
(Zolmitriptan )
add to watch list
Paper trade
email alert is off
Press-releases
Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
Published: 2024-04-24
(Crawled : 14:00)
- biospace.com/
AMRX
|
$6.05
12.04%
11.04%
2.7M
|
Health Technology
| 12.04%
| O: 6.67%
H: 6.08%
C: 5.03%
fda
opioid
approval
treatment
for
spray
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
Published: 2024-04-16
(Crawled : 14:00)
- biospace.com/
AMRX
|
$6.05
12.04%
11.04%
2.7M
|
Health Technology
| 9.21%
| O: -1.08%
H: 1.09%
C: -0.55%
rtu
first
Amneal to Report First Quarter 2024 Results on May 3, 2024
Published: 2024-04-10
(Crawled : 13:00)
- biospace.com/
AMRX
|
$6.05
12.04%
11.04%
2.7M
|
Health Technology
| 5.58%
| O: -0.52%
H: 3.86%
C: 0.0%
first
report
results
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
Published: 2024-03-25
(Crawled : 23:00)
- biospace.com/
AMRX
|
$6.05
12.04%
11.04%
2.7M
|
Health Technology
| -0.33%
| O: 0.0%
H: 0.33%
C: -2.64%
fda
approval
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
Published: 2024-02-27
(Crawled : 14:00)
- biospace.com/
AMRX
|
$6.05
12.04%
11.04%
2.7M
|
Health Technology
| 3.95%
| O: -1.89%
H: 1.75%
C: 0.0%
ipx203
biotech
agreement
Amneal to Participate at Upcoming Investor Conference
Published: 2024-02-13
(Crawled : 13:30)
- biospace.com/
AMRX
|
$6.05
12.04%
11.04%
2.7M
|
Health Technology
| 3.42%
| O: -3.84%
H: 2.57%
C: -0.45%
conference
Amneal Announces Complete Response Resubmission for IPX203 New Drug Application
Published: 2024-02-08
(Crawled : 21:00)
- globenewswire.com
AMRX
|
$6.05
12.04%
11.04%
2.7M
|
Health Technology
| 10.81%
| O: 0.18%
H: 1.83%
C: 1.83%
ipx203
drug
resubmission
application
response
I-Mab Signs Agreement to Divest its Assets and Business Operations in China
Published: 2024-02-07
(Crawled : 11:00)
- prnewswire.com
AMRX
|
$6.05
12.04%
11.04%
2.7M
|
Health Technology
| 8.04%
| O: 0.0%
H: 0.0%
C: -4.29%
IMAB
|
$1.81
0.56%
0.28%
110K
|
Health Technology
| -9.95%
| O: 2.49%
H: 0.97%
C: -2.91%
business
agreement
china
Deb Autor, Former FDA Deputy Commissioner, Appointed CEO of Healthcare Innovation Catalysts
Published: 2024-02-01
(Crawled : 13:00)
- biospace.com/
AMRX
|
$6.05
12.04%
11.04%
2.7M
|
Health Technology
| 13.08%
| O: 2.8%
H: 0.55%
C: 0.18%
fda
ceo
innovation
Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203
Published: 2024-01-25
(Crawled : 12:30)
- globenewswire.com
AMRX
|
$6.05
12.04%
11.04%
2.7M
|
Health Technology
| 11.42%
| O: 1.57%
H: 0.73%
C: -0.82%
ipx203
license
pharmaceuticals
therapeutics
agreement
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount
0001628280-24-009481
4
2024-03-06
2024-03-04
Buy
A
1333334
1333334
0001628280-24-009481
4
2024-03-06
2024-03-04
Buy
A
370370
370370
0001628280-24-009480
4
2024-03-06
2024-03-04
Buy
A
1333334
1333334
0001628280-24-009480
4
2024-03-06
2024-03-04
Buy
A
370370
370370